Literature DB >> 20580502

SERMs: progress and future perspectives.

James H Pickar1, Tanya MacNeil, Kathleen Ohleth.   

Abstract

Selective estrogen receptor modulators (SERMs) interact with estrogen receptors as agonists or antagonists depending on the target tissue. Currently available SERMs are used to treat and prevent breast cancer and osteoporosis, to treat ovulatory dysfunction in women, and for contraception. Because current therapies do not adequately treat menopausal symptoms, the search continues for the optimal SERM for postmenopausal women, which would relieve hot flushes, treat vaginal atrophy, and prevent fractures, while protecting the endometrium, breast, and cardiovascular system. Future use of SERMs may also include their use in a tissue selective estrogen complex (TSEC), a therapy that combines a SERM with estrogen(s), designed to deliver the efficacy of each component with improved overall tolerability for the treatment of postmenopausal women. The future of SERMs may also include their use in men for the treatment of osteoporosis and various syndromes associated with secondary hypogonadism and possibly prostate cancer. Continued research should allow the full potential of SERMs to be uncovered.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20580502     DOI: 10.1016/j.maturitas.2010.05.009

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  20 in total

1.  Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes.

Authors:  F Cerrato; M E Fernández-Suárez; R Alonso; M Alonso; C Vázquez; O Pastor; P Mata; M A Lasunción; D Gómez-Coronado
Journal:  Br J Pharmacol       Date:  2015-01-08       Impact factor: 8.739

2.  The naphthol selective estrogen receptor modulator (SERM), LY2066948, is oxidized to an o-quinone analogous to the naphthol equine estrogen, equilenin.

Authors:  Teshome B Gherezghiher; Bradley Michalsen; R Esala P Chandrasena; Zhihui Qin; Johann Sohn; Gregory R J Thatcher; Judy L Bolton
Journal:  Chem Biol Interact       Date:  2012-01-28       Impact factor: 5.192

3.  Selective estrogen receptor modulator (SERM) lasofoxifene forms reactive quinones similar to estradiol.

Authors:  Bradley T Michalsen; Teshome B Gherezghiher; Jaewoo Choi; R Esala P Chandrasena; Zhihui Qin; Gregory R J Thatcher; Judy L Bolton
Journal:  Chem Res Toxicol       Date:  2012-06-14       Impact factor: 3.739

Review 4.  Structural dynamics, intrinsic disorder, and allostery in nuclear receptors as transcription factors.

Authors:  Vincent J Hilser; E Brad Thompson
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

5.  Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.

Authors:  Shiyi Yu; Xue Gong; Zhifang Ma; Meng Zhang; Ling Huang; Jun Zhang; Shuang Zhao; Tao Zhu; Zhenghong Yu; Liming Chen
Journal:  Cell Oncol (Dordr)       Date:  2019-11-07       Impact factor: 6.730

6.  The effects of bazedoxifene in the ovariectomized aged cynomolgus monkey.

Authors:  Susan Y Smith; Jacquelin Jolette; Luc Chouinard; Barry S Komm
Journal:  J Bone Miner Metab       Date:  2014-03-16       Impact factor: 2.626

7.  Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.

Authors:  Fredrik Erlandsson; Muna Albayaty; Ligia Chialda; Hans Ericsson; Carl Amilon; Karin Nelander; Rasmus Jansson-Löfmark; Linda Wernevik; Magnus Kjaer; Krister Bamberg; Judith Hartleib-Geschwindner
Journal:  Br J Clin Pharmacol       Date:  2018-04-22       Impact factor: 4.335

8.  "All in the mind"? Brain-targeting chemical delivery system of 17β-estradiol (Estredox) produces significant uterotrophic side effect.

Authors:  Katalin Prokai-Tatrai; Szabolcs Szarka; Vien Nguyen; Fatima Sahyouni; Cary Walker; Shastazia White; Tatjana Talamantes; Laszlo Prokai
Journal:  Pharm Anal Acta       Date:  2012

9.  Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen.

Authors:  Jinzhong Liu; Peter J Flockhart; Deshun Lu; Wei Lv; Wenjie Jessie Lu; Xu Han; Mark Cushman; David A Flockhart
Journal:  Drug Metab Dispos       Date:  2013-07-03       Impact factor: 3.922

10.  Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells.

Authors:  Liang Xu; Jingyu Lei; Donghai Jiang; Lin Zhou; Shu Wang; Weimin Fan
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.